Monacef (Cefuroxime Sodium)

Cefuroxime sodium, the active ingredient in Monacef, is a cephalosporin presented as a sterile solution for intramuscular and intravenous use. It treats a broad range of bacterial infections in adult and pediatric patients as determined by a prescriber.

GNH USA supplies Monacef as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Monacef, a third‑generation cephalosporin, is employed to manage infections caused by susceptible bacteria.

- Community‑acquired pneumonia: eradicates the causative pathogens and improves respiratory function. - Acute bacterial sinusitis: reduces sinus inflammation and clears infection. - Skin and soft‑tissue infections: eliminates staphylococcal and streptococcal organisms. - Urinary tract infections: treats uncomplicated cystitis caused by susceptible strains. - Gonorrhea: provides an alternative therapy for Neisseria gonorrhoeae infections. - Bacterial meningitis (adjunct): contributes to bacterial clearance when combined with other agents.

Cefuroxime sodium may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Diarrhea: mild to moderate loose stools. - Nausea: occasional feeling of queasiness. - Injection site pain: localized discomfort after IM/IV administration. - Rash: transient erythematous skin eruptions. - Elevated liver enzymes: mild, reversible changes in hepatic function tests.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Clostridioides difficile colitis: severe intestinal inflammation. - Hemolytic anemia: destruction of red blood cells. - Stevens‑Johnson syndrome: severe mucocutaneous disorder. - Renal impairment: acute kidney injury in susceptible patients. - Thrombocytopenia: reduced platelet count leading to bleeding risk.

Before initiating therapy with Monacef, consider the following safety measures.

- Allergy assessment: confirm no known hypersensitivity to cephalosporins or penicillins. - Renal function: adjust dose in patients with impaired kidney function. - Hepatic status: monitor liver enzymes in patients with pre‑existing liver disease. - Pregnancy and lactation: use only if the potential benefit outweighs risk; consult obstetric guidance. - Concomitant antibiotics: avoid unnecessary combination to reduce resistance development. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Cefuroxime sodium can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Probenecid: reduces renal excretion, increasing cefuroxime plasma levels and toxicity risk. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may increase nephrotoxicity; monitor renal function. - Oral contraceptives: potential reduction in contraceptive efficacy; advise backup method. - Aminoglycosides: additive nephrotoxic potential; assess kidney function regularly. - Live vaccines: antibiotic may diminish vaccine effectiveness; schedule appropriately.